Recruiting studies: Newly Diagnosed Multiple Myeloma Ndmm

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

Study for Frail Patients With Newly Diagnosed Multiple Myeloma Treated With Daratumumab With Teclistamab or Talquetamab.
Phase 2 · 29 location(s) · European Myeloma Network B.V. · NCT07107529 Real-world Immuno-therapy in Chinese Newly Diagnosed Multiple Myeloma Patients
Phase N/A · 1 location(s) · Peking University People's Hospital · NCT07296627 Isatuximab-VRd in Transplant-Ineligible Newly Diagnosed Multiple Myeloma Patients
Phase N/A · 13 location(s) · Shanghai Zhongshan Hospital · NCT07663253 Elranatamab/Lenalidomide Consolidation and/or Elranatamab Maintenance Versus Standard of Care After D-VRd Induction in T
Phase 3 · 64 location(s) · Intergroupe Francophone du Myelome · NCT06918002 Individualized Dynamic Frailty-tailored Therapy (DynaFiT) in Elderly Patients With NDMM
Phase N/A · 1 location(s) · FengYan Jin · NCT06099912 Positron Emission Tomography With Innovative Laboratory Techniques for Improved Risk and Disease Assessment in Newly Dia
Phase N/A · 4 location(s) · Universiteit Antwerpen · NCT07087964 A Window of Opportunity Trial to Learn if Linvoseltamab is Safe and Well Tolerated, and How Well it Works in Adult Parti
Phase 1/Phase 2 · 32 location(s) · Regeneron Pharmaceuticals · NCT05828511 Conversion to Carfilzomib Therapy in Bortezomib Intolerant Newly Diagnosed Multiple Myeloma(NDMM) Patients
Phase N/A · 1 location(s) · The First Affiliated Hospital of Soochow University · NCT06682156 Horizon Two: HR NDMM (MMRC-100)
Phase 2 · 7 location(s) · Multiple Myeloma Research Consortium · NCT07053436 KPD Consolidation After ASCT in NDMM Patients
Phase 2/Phase 3 · 3 location(s) · Peking University People's Hospital · NCT06879379 Linvoseltamab in Addition to Lenalidomide (L2) During Maintenance Therapy of NDMM to Deepen Responses or Redrive MRD Neg
Phase 2 · 1 location(s) · Dickran Kazandjian, MD · NCT06910124 Frontline T-cell Engager vs Autologous Stem Cell Transplant (ASCT) and Measurable Residual Disease (MRD)-Guided Sequenti
Phase 2 · 11 location(s) · SCRI Development Innovations, LLC · NCT06974786 Comparing Combinations of Drugs to Treat Newly Diagnosed Multiple Myeloma (NDMM) When a Stem Cell Transplant is Not a Me
Phase 3 · 397 location(s) · SWOG Cancer Research Network · NCT05561387 18F-Fluciclovine PET/CT in Multiple Myeloma
Phase 2 · 1 location(s) · National Cancer Institute (NCI) · NCT06103838 A Study of Belantamab Mafodotin Administered in Combination With Lenalidomide and Dexamethasone (BRd) Versus Daratumumab
Phase 3 · 181 location(s) · GlaxoSmithKline · NCT06679101 SVRd for the Treatment of Newly Diagnosed Multiple Myeloma Patients Presenting With Extramedullary Disease
Phase 2 · 6 location(s) · The First Affiliated Hospital with Nanjing Medical Universit · NCT05900882 NDMM Patients Candidates for ASCT Comparing Extended VRD Plus vs. Isa-VRD vs. Isa-V-Iberdomide
Phase 3 · 68 location(s) · PETHEMA Foundation · NCT05558319 Safety and Efficacy of RN1201 Injection as First-Line Treatment for Newly Diagnosed Multiple Myeloma
Phase 1 · 1 location(s) · The First Affiliated Hospital of Soochow University · NCT07652138

Look up another condition

Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.